What is the appropriate workup for a patient with a ten‑day history of severe diffuse pain unresponsive to standard analgesics to evaluate for inflammatory myopathy (myositis)?

Myositis Workup

For a patient with severe diffuse pain unresponsive to standard analgesics, immediately measure creatine kinase (CK) and troponin levels, as CK elevation ≥3x upper limit of normal distinguishes true inflammatory myositis from pain-predominant syndromes, and troponin elevation identifies life-threatening myocardial involvement that carries 20% mortality risk. 1, 2

Initial Laboratory Assessment

Essential immediate tests:

• CK and aldolase - CK is the most critical test; elevations ≥3x ULN indicate muscle inflammation requiring urgent treatment. Median CK in confirmed myositis is 2650 IU/L (range 335-20,270 IU/L). Normal CK essentially rules out myositis in favor of pain syndromes like polymyalgia rheumatica. 1, 2
• Troponin - Mandatory to evaluate myocardial involvement, which is frequently associated with myositis and dramatically increases mortality. 1, 2
• Transaminases (AST, ALT) and LDH - Can be elevated in myositis but are less specific than CK. 1
• ESR and CRP - Inflammatory markers help distinguish inflammatory myositis from other causes. 1, 2

Autoantibody testing:

• Myositis-specific autoantibodies - Including anti-Jo1, anti-TIF1γ, anti-NXP2, anti-SRP, anti-PM/Scl, and anti-PL-7/PL-12, though these are negative in many cases. 1
• Anti-acetylcholine receptor and anti-striated muscle antibodies - To evaluate for concomitant myasthenia gravis, which occurs in 12.5% of myositis cases and significantly worsens prognosis. 1
• Urinalysis - For rhabdomyolysis detection. 1

Critical Clinical Examination

Focus on distinguishing features:

• Proximal muscle weakness assessment - True weakness (difficulty standing from chair, lifting arms overhead, climbing stairs) is the hallmark of myositis, whereas pain without weakness suggests polymyalgia rheumatica or other pain syndromes. 1, 2
• Skin examination - Look for heliotrope rash, Gottron papules, periorbital edema, V-sign, shawl sign, mechanic's hands (dermatomyositis features). 1, 2
• Neurologic examination - Assess for ptosis, diplopia, dysphagia, dysarthria, dysphonia (suggesting myasthenia gravis overlap), and dropped head syndrome. 1
• Cardiac symptoms - Dyspnea, palpitations, chest pain, or syncope indicate possible myocarditis requiring immediate intervention. 1
• Respiratory assessment - Evaluate for bulbar symptoms and respiratory muscle weakness. 1

Cardiac Evaluation (Mandatory)

All patients with suspected myositis require cardiac assessment:

• ECG - Baseline assessment for conduction abnormalities. 1
• Echocardiogram or cardiac MRI - If troponin elevated, ECG abnormal, or any cardiac symptoms present. Cardiac MRI shows myocardial inflammation in >60% of inflammatory myopathy patients. 1

Critical pitfall: Normal cardiac enzymes cannot completely rule out myocarditis; maintain high clinical suspicion with any cardiac symptoms. 1

Advanced Diagnostic Studies

Electromyography (EMG):

• Consider when diagnosis is uncertain or neurologic overlap syndromes (myasthenia gravis) suspected. 1, 2
• Classic findings include polyphasic motor unit action potentials of short duration/low amplitude, increased insertional activity, fibrillation potentials, and sharp waves. 1
• Important caveat: EMG can be negative in some myositis cases, particularly immune-mediated necrotizing myopathy. 3

MRI of affected proximal limbs:

• T1-weighted, T2-weighted, and fat suppression sequences (STIR) identify muscle inflammation and guide biopsy site selection. 1, 2, 4, 5, 6
• Whole-body MRI provides comprehensive assessment of disease extent and distribution, particularly valuable for bilateral symmetrical involvement. 5
• MRI can detect inflammation before clinical symptoms appear and serves as baseline for treatment monitoring. 4, 5, 6

Muscle biopsy:

• Consider when diagnosis remains uncertain after initial workup, when EMG and autoantibodies are negative, or when overlap with other conditions is suspected. 1, 7, 3
• Not systematically required when clinical presentation and autoantibodies are typical. 7
• Biopsy is crucial for distinguishing immune-mediated necrotizing myopathy (minimal inflammation, extensive necrosis) from polymyositis (CD8+ T-cell invasion) or inclusion body myositis (vacuolization, amyloid deposits). 1, 7, 3

Severity-Based Workup Algorithm

Grade 1 (Mild weakness with/without pain):

• Complete examination and full laboratory workup as above. 1

Grade 2 (Moderate weakness limiting instrumental activities):

• Complete history/examination, autoimmune myositis panel, EMG, MRI of affected limbs. 1, 2
• Consider muscle biopsy if diagnosis uncertain. 1
• Early referral to rheumatology or neurology. 1, 2

Grade 3-4 (Severe weakness limiting self-care):

• Same as Grade 2 workup. 1
• Urgent referral to rheumatology or neurology. 1, 2
• Consider hospitalization for severe cases. 2

Key Differential Considerations

Distinguish from polymyalgia rheumatica-like syndrome:

• Polymyalgia presents with severe pain but not true weakness. 1
• CK levels are normal in polymyalgia (critical distinguishing feature). 1
• EMG and MRI show no evidence of myopathy in polymyalgia. 1

Other differentials to exclude:

• Statin-induced myopathy (consider holding statins during workup). 1
• Fibromyalgia (normal CK, no weakness). 1
• Paraneoplastic syndromes (warrant malignancy screening). 1

Monitoring Parameters

Serial assessments:

• CK, ESR, CRP every 1-2 weeks initially, then every 4-6 weeks. 1, 2
• Troponin monitoring if any cardiac symptoms develop. 2
• Functional muscle strength assessment at each visit. 2